par Rouamba, Toussaint ;Sondo, Paul;Derra, Karim;Nakanabo-Diallo, Seydou;Bihoun, Biebo;Rouamba, Eli;Tarnagda, Zekiba;Kazienga, Adama;Valea, Innocent;Sorgho, Hermann;Pagnoni, Franco;Kirakoya, Fati ;Tinto, Halidou
Référence Drug Design, Development and Therapy, 14, page (1507-1521)
Publication Publié, 2020-05-01
Référence Drug Design, Development and Therapy, 14, page (1507-1521)
Publication Publié, 2020-05-01
Article révisé par les pairs
Résumé : | Resource-limited countries face challenges in setting up effective pharmacovigilance systems. This study aimed to monitor the occurrence of adverse events (AEs) after the use of artemisinin-based combination therapies (ACTs), identify potential drivers of reporting suspected adverse drug reactions (ADRs) and monitor AEs among women who were inadvertently exposed to ACTs in the first trimester of pregnancy. |